TSN1611

TSN1611 is a highly selective and orally bioavailable small molecule inhibitor that targets the KRAS G12D mutant protein, a key oncogenic driver in several solid tumors including pancreatic, colorectal, and lung cancers. By specifically binding to both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS G12D, TSN1611 blocks downstream signaling pathways essential for tumor cell survival and proliferation. Preclinical studies have demonstrated potent anti-tumor activity with favorable pharmacokinetic properties and brain penetration potential. The drug is currently in Phase 2 clinical trials for multiple advanced solid tumors harboring the KRAS G12D mutation.

Other names

KRAS G12D inhibitor TSN1611